Company recognised for sponsor/site relationship quality
LONDON, April 3, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced that it was named a top contract research organisation (CRO) in the CenterWatch 2017 Global Investigative Site Relationship Survey. The survey recognises CROs that have high-quality working relationships with investigative sites.
The survey, published today in CenterWatch Monthly, polled over 1,300 global investigative sites on aspects of their relationships with CROs during the past two years. PAREXEL ranked among the top five highest-rated CROs for the overall quality of its direct working relationships with investigative sites. In particular, PAREXEL ranked high in categories such as professional and efficient administrative staff; professional, knowledgeable, and well-trained monitors; understanding of local regulatory/ethics issues; and conduct of clear study initiation visits and training.
“Across the industry, the relationship between CROs and sites has become more strategic. To address this need, we have developed a tailored approach that helps us foster long-term quality partnerships,” said Paul Evans, Corporate Vice President, Global Site Strategy, PAREXEL. “PAREXEL’s high ranking is a reflection of our commitment to our clients and their journeys to bring new treatments to patients in need.”
PAREXEL’s global Site Alliance Network is a significant component of the Company’s approach. The network is comprised of 300 sites with dedicated PAREXEL relationship managers. These individuals also work with key site management organisations (SMOs) to reach an additional 250 sites. The network includes strategic collaborations with Academic Research Organizations on two continents and managed relationships that extend beyond single studies.
PAREXEL continuously solicits feedback from site staff to enhance its support. This enables faster patient recruitment, evaluation, and enrollment in clinical trials. Additionally, the feedback ensures quality and fosters greater collaboration between PAREXEL and sites.
“We focus on simplifying trial execution for busy sites and their staff through our dedicated on-site clinical research associates, office-based monitors, and other support functions,” said Karen Chu, Corporate Vice President, Global Clinical Operations, PAREXEL. “The CenterWatch survey results are a testament to our focus on delivering effective and timely support for our sites and our clients.”
CenterWatch’s 2017 Global Investigative Site Relationship Survey was conducted online between October 2016 and January 2017. The survey included participation from principal investigators, study coordinators, and other clinical research professionals from 1,376 sites. More than 80 percent of the sites were from North America and Europe. The survey, first launched in 1997, uses an instrument to measure sponsor/site relationship quality based on input from representatives from sponsor and CRO companies and investigative sites.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 51 countries around the world, and had approximately 19,625 employees in the second quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #
Charlotte Bass/ Ivelina Adzheva
OneChocolate for PAREXEL
Tel.: +44 (0)20 7437 0227
Tel.: +1 781-434-4753